Cargando…

Manifestations neurologiques associées au COVID-19

INTRODUCTION: The COVID-19 pandemic highlighted the existence of neurological manifestations associated with SARS-CoV-2 infection. The aim of this review was to summarize the prevalence and the range of neurological manifestations associated with COVID-19, and to expose the main hypotheses about the...

Descripción completa

Detalles Bibliográficos
Autores principales: Meppiel, E., De Broucker, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972803/
http://dx.doi.org/10.1016/j.praneu.2021.03.002
_version_ 1783666717565648896
author Meppiel, E.
De Broucker, T.
author_facet Meppiel, E.
De Broucker, T.
author_sort Meppiel, E.
collection PubMed
description INTRODUCTION: The COVID-19 pandemic highlighted the existence of neurological manifestations associated with SARS-CoV-2 infection. The aim of this review was to summarize the prevalence and the range of neurological manifestations associated with COVID-19, and to expose the main hypotheses about the pathogenic pathways based on available neuropathological studies. METHODS: Articles have been identified by searches of PubMed and Google scholar up to November 15, 2020, using a combination of COVID-19 and neurology search terms and adding relevant references in the articles. RESULTS: Nonspecific neurological symptoms such as headache, dizziness, pain and myalgia, have been reported in 2 to 30% of COVID-19 hospitalized patients. More severe neurological diseases affected 8 to 13% of COVID-19 hospitalized patients including various central or peripheral manifestations. Among central nervous system involvement, encephalopathy and cerebrovascular disease – especially ischemic stroke – were the most frequent, followed by encephalitis, myelitis, meningitis, and posterior reversible encephalopathy syndrome. Guillain–Barré syndrome and variants were the most common form of peripheral nervous system involvement, followed by critical illness neuromyopathy, plexopathy, polyneuropathy, oculomotor neuropathy, and Tapia syndrome. Encephalopathy, ischemic stroke and encephalitis occurred 6 to 12 days in median after the first signs of COVID-19, while Guillain–Barré syndrome occured later, at 15 to 23 days in median. Taste and smell disorders affected 34 to 86% of patients and occurred 3.5 days in median after the onset of infection. Pathogenic pathways of nervous system involvement in COVID-19 remain poorly understood. Neuropathological studies highlighted the possible role of sepsis and hypoxia, endothelial infection/dysfunction, inflammation and immune-mediated disease. While the presence of SARS-CoV-2 in the brain was confirmed in some COVID-19 patients, there were no definite evidence to support its direct pathogenicity on brain parenchyma. CONCLUSION: Neurological involvement in COVID-19 is frequent and includes various manifestations. Most of them are encephalopathies and strokes, probably linked to viral sepsis, hypoxia and/or endotheliitis. A wide range of post-infectious disorders was also reported, such as encephalitis and Guillain–Barré syndrome. To date no studies demonstrated definite evidence of a direct pathogenicity of SARS-CoV-2 on brain.
format Online
Article
Text
id pubmed-7972803
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-79728032021-03-19 Manifestations neurologiques associées au COVID-19 Meppiel, E. De Broucker, T. Pratique Neurologique Neurologie Infectieuse INTRODUCTION: The COVID-19 pandemic highlighted the existence of neurological manifestations associated with SARS-CoV-2 infection. The aim of this review was to summarize the prevalence and the range of neurological manifestations associated with COVID-19, and to expose the main hypotheses about the pathogenic pathways based on available neuropathological studies. METHODS: Articles have been identified by searches of PubMed and Google scholar up to November 15, 2020, using a combination of COVID-19 and neurology search terms and adding relevant references in the articles. RESULTS: Nonspecific neurological symptoms such as headache, dizziness, pain and myalgia, have been reported in 2 to 30% of COVID-19 hospitalized patients. More severe neurological diseases affected 8 to 13% of COVID-19 hospitalized patients including various central or peripheral manifestations. Among central nervous system involvement, encephalopathy and cerebrovascular disease – especially ischemic stroke – were the most frequent, followed by encephalitis, myelitis, meningitis, and posterior reversible encephalopathy syndrome. Guillain–Barré syndrome and variants were the most common form of peripheral nervous system involvement, followed by critical illness neuromyopathy, plexopathy, polyneuropathy, oculomotor neuropathy, and Tapia syndrome. Encephalopathy, ischemic stroke and encephalitis occurred 6 to 12 days in median after the first signs of COVID-19, while Guillain–Barré syndrome occured later, at 15 to 23 days in median. Taste and smell disorders affected 34 to 86% of patients and occurred 3.5 days in median after the onset of infection. Pathogenic pathways of nervous system involvement in COVID-19 remain poorly understood. Neuropathological studies highlighted the possible role of sepsis and hypoxia, endothelial infection/dysfunction, inflammation and immune-mediated disease. While the presence of SARS-CoV-2 in the brain was confirmed in some COVID-19 patients, there were no definite evidence to support its direct pathogenicity on brain parenchyma. CONCLUSION: Neurological involvement in COVID-19 is frequent and includes various manifestations. Most of them are encephalopathies and strokes, probably linked to viral sepsis, hypoxia and/or endotheliitis. A wide range of post-infectious disorders was also reported, such as encephalitis and Guillain–Barré syndrome. To date no studies demonstrated definite evidence of a direct pathogenicity of SARS-CoV-2 on brain. Published by Elsevier Masson SAS. 2021-05 2021-03-19 /pmc/articles/PMC7972803/ http://dx.doi.org/10.1016/j.praneu.2021.03.002 Text en © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Neurologie Infectieuse
Meppiel, E.
De Broucker, T.
Manifestations neurologiques associées au COVID-19
title Manifestations neurologiques associées au COVID-19
title_full Manifestations neurologiques associées au COVID-19
title_fullStr Manifestations neurologiques associées au COVID-19
title_full_unstemmed Manifestations neurologiques associées au COVID-19
title_short Manifestations neurologiques associées au COVID-19
title_sort manifestations neurologiques associées au covid-19
topic Neurologie Infectieuse
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972803/
http://dx.doi.org/10.1016/j.praneu.2021.03.002
work_keys_str_mv AT meppiele manifestationsneurologiquesassocieesaucovid19
AT debrouckert manifestationsneurologiquesassocieesaucovid19